Antibody Drug Conjugates Contract Manufacturing Market Report 2024

This Antibody Drug Conjugates Contract Manufacturing market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The antibody drug conjugates contract manufacturing market size has grown strongly in recent years. It will grow from $8.72 billion in 2023 to $9.57 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be linked to the rising incidence of cancer, an increased demand for targeted therapies, advancements in antibody-drug conjugates, higher investments in research and development, regulatory approvals for new ADCs, and the expansion of pharmaceutical companies.

The antibody drug conjugates contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $14.0 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The growth anticipated during the forecast period is driven by the expected rise of personalized medicine, expanding uses of antibody-drug conjugates (ADCs) beyond oncology, increasing partnerships between biotech and pharmaceutical companies, a greater adoption of ADCs in clinical trials, and a growing focus on cost-effective manufacturing solutions. Key trends expected in this period include progress in biomarker identification, advancements in biotechnology, a higher adoption of next-generation ADC technologies, improvements in linker and payload technologies, and the integration of artificial intelligence in drug development.

The expanding biopharmaceutical industry is anticipated to drive the growth of the antibody-drug conjugates (ADCs) contract manufacturing market in the future. This industry is centered on the development, production, and commercialization of drugs derived from biological sources, employing biotechnology and molecular biology to create innovative therapies and treatments. Factors contributing to the growth of the biopharmaceutical sector include rapid advancements in biotechnology, increasing demand for personalized medicine, and rising investments in research and development aimed at new therapies. ADCs contract manufacturing plays a crucial role in supporting the biopharmaceutical industry by providing specialized production services that facilitate the development and commercialization of these advanced therapies. This allows biopharmaceutical companies to efficiently scale up production while maintaining high-quality standards, enabling them to focus on their primary research and development efforts. For example, in May 2024, the Department of Health and Social Care, a UK government agency, reported that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue for the year 2021/22, which represented 43% of the entire life sciences industry. Consequently, the growth of the biopharmaceutical sector is propelling the antibody-drug conjugates contract manufacturing market forward.

Key players in the antibody-drug conjugates contract manufacturing market are concentrating on creating innovative solutions, such as single-use reactors, to improve production flexibility, minimize contamination risks, and streamline the manufacturing process, ultimately enhancing the efficiency and scalability of ADC production. Single-use reactors are transforming ADC contract manufacturing by providing a flexible, efficient, and contamination-free option for producing these complex biologics. For instance, in September 2024, MilliporeSigma, a US-based life science company, introduced the Mobius ADC Reactor, designed specifically for the efficient manufacturing of antibody-drug conjugates. This reactor incorporates advanced mixing and control technologies that facilitate conjugation, enhance scalability, and improve consistency. The Mobius ADC Reactor supports higher yields and better quality control in ADC production, catering to the increasing demand for targeted cancer therapies that offer improved safety and efficacy.

In March 2024, Johnson & Johnson, a US-based corporation involved in pharmaceuticals, biotechnology, and medical technologies, acquired Ambrx Biopharma Inc. for $2 billion. This acquisition aims to strengthen Johnson & Johnson's portfolio of advanced therapies by incorporating Ambrx's innovative drug development technologies and enhancing its capabilities in biologics and targeted treatments. Ambrx Biopharma Inc. is a US-based biotechnology company dedicated to developing cutting-edge therapies, including antibody-drug conjugates (ADCs).

Major companies operating in the antibody drug conjugates contract manufacturing market are AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim, Recipharm AB, Sigma-Aldrich, Sartorius AG, Curia, Lonza Group AG, Catalent Inc., KBI Biopharma, Alcami Corporation, Formosa Laboratories, BioVectra Inc., Axplora, Abzena PLC, ImmunoGen Inc., EirGenix Inc., Avid Bioservices Inc., Mersana Therapeutics, Cerbios-Pharma SA, Creative Biolabs, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions.

North America was the largest region in the antibody drug conjugates contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the antibody drug conjugates contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antibody-drug conjugates (ADC) contract manufacturing involves outsourcing the production of these specialized biopharmaceuticals to contract development and manufacturing organizations (CDMOs). ADCs are intricate compounds that merge an antibody with a cytotoxic drug, specifically designed to target and eliminate certain cancer cells while reducing harm to healthy cells.

The primary types of ADC contract manufacturing include immunoglobulin G1 (IgG1) and immunoglobulin G4 (IgG4). IgG1 is one of the four subclasses of immunoglobulin G, which is an antibody present in blood and extracellular fluid. Various types of linkers used in ADCs include cleavable linkers and non-cleavable linkers, which are employed for conditions such as myeloma, lymphoma, and breast cancer, among others, and are utilized in different phases, including clinical and commercial production.

The antibody-drug conjugates contract manufacturing market research report is one of a series of new reports that provides antibody-drug conjugates contract manufacturing market statistics, including antibody-drug conjugates contract manufacturing industry global market size, regional shares, competitors with an antibody-drug conjugates contract manufacturing market share, detailed antibody-drug conjugates contract manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the antibody-drug conjugates contract manufacturing industry. This antibody-drug conjugates contract manufacturing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antibody drug conjugates contract manufacturing market includes revenues earned by entities by providing process development, scale-up and manufacturing, analytical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.